Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy

• Published in: Cell research Vol. 29; no. 6; pp. 446 - 459
• Main Authors: Mugoni, Vera, Panella, Riccardo, Cheloni, Giulia, Chen, Ming, Pozdnyakova, Olga, Stroopinsky, Dina, Guarnerio, Jlenia, Monteleone, Emanuele, Lee, Jonathan David, Mendez, Lourdes, Menon, Archita Venugopal, Aster, Jon Christopher, Lane, Andrew A, Stone, Richard Maury, Galinsky, Ilene, Zamora, José Cervera, Lo-Coco, Francesco, Bhasin, Manoj Kumar, Avigan, David, Longo, Letizia, Clohessy, John Gerard, Pandolfi, Pier Paolo
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.06.2019; Nature Publishing Group UK
• Subjects: Animals; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Arsenic; Arsenic trioxide; Arsenic Trioxide - pharmacology; Combinatorial analysis; Dependence; Disease Models, Animal; Evolution; Genotoxicity; Glutathione; Humans; Isocitrate Dehydrogenase - antagonists & inhibitors; Isocitrate Dehydrogenase - genetics; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Leukemia, Promyelocytic, Acute - drug therapy; Leukemia, Promyelocytic, Acute - genetics; Leukemia, Promyelocytic, Acute - pathology; Metabolism; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Neoplasms, Experimental - drug therapy; Neoplasms, Experimental - genetics; Neoplasms, Experimental - pathology; Pin1 protein; Reactive oxygen species; Retinoic acid; Therapy; Transcription; Tretinoin; Tretinoin - pharmacology; Tumor Cells, Cultured; U937 Cells
• ISSN: 1001-0602; 1748-7838
• DOI: 10.1038/s41422-019-0162-7

Although targeted therapies have proven effective and even curative in human leukaemia, resistance often ensues. IDH enzymes are mutated in ~20% of human AML, with targeted therapies under clinical evaluation. We here characterize leukaemia evolution from mutant IDH2 (mIDH2)-dependence to independence identifying key targetable vulnerabilities of mIDH2 leukaemia that are retained during evolution and progression from early to late stages. Mechanistically, we find that mIDH2 leukaemia are metastable and vulnerable at two distinct levels. On the one hand, they are characterized by oxidative and genotoxic stress, in spite of increased 1-carbon metabolism and glutathione levels. On the other hand, mIDH2 leukaemia display inhibition of LSD1 and a resulting transcriptional signature of all-trans retinoic acid (ATRA) sensitization, in spite of a state of suppressed ATRA signalling due to increased levels of PIN1. We further identify GSH/ROS and PIN1/LSD1 as critical nodes for leukaemia maintenance and the combination of ATRA and arsenic trioxide (ATO) as a key therapeutic modality to target these vulnerabilities. Strikingly, we demonstrate that the combination of ATRA and ATO proves to be a powerfully synergistic and effective therapy in a number of mouse and human mIDH1/2 leukemic models. Thus, our findings pave the way towards the treatment of a sizable fraction of human AMLs through targeted APL-like combinatorial therapies.